SIGNIFICANT MILESTONE FOR HIV PREVENTION IN SUB-SAHARAN AFRICA AS SOUTH AFRICA GRANTS REGULATORY APPROVAL FOR APRETUDE
We are extremely pleased to share the news that, the South African Health Products Regulatory Authority (SAHPRA) has granted regulatory approval of Apretude (cabotegravir long-acting injectable), the first and only long-acting option for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1.
Approval of cabotegravir long-acting for PrEP in South Africa was supported by data from two international phase IIb/III multicentre, randomised, double-blind, active controlled studies, HPTN 083 and HPTN 084, which evaluated the safety and efficacy of cabotegravir long-acting for PrEP in HIV-negative men who have sex with men, transgender women, and cisgender women who were at increased risk of HIV. South Africa was the only country to take part in both studies. Regulatory submissions are currently underway in the other countries that took part in the HPTN083 and 084 studies.
South Africa bears the greatest burden of HIV worldwide and this is felt most significantly by women and young girls, where challenges with adherence, and stigma have hindered the potential impact of current PrEP are actively working with global partners to make Apretude an available prevention option for those who could benefit from PrEP. Following approval in South Africa, we look forward to seeing continued progress to help enable access.
Cabotegravir long-acting for PrEP is currently approved in the US, Australia, Zimbabwe and South Africa as Apretude. For more information on submissions around the world, please visit our website.
Media contacts
For our corporate press office, email: Rachel Jaikaran
OR call +44 7823 523 755
For US-specific media enquiries,email: Audrey Abernathy
OR call +1 919 605 4521
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellowcard in the Google Play or Apple App store. By reporting side effects, you can help provide more information on the safety of this medicine.
If you are from outside the UK, you can report adverse events to GSK/ViiV by selecting your region and market, here.
